B. Sandmaier

发表

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

M. Sorror, M. Maris, R. Storb, 2005, Blood.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

F. Baron, B. Sandmaier, 2006, Leukemia.

A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients

M. Sorror, B. Sandmaier, J. McCune, 2013, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration

B. Sandmaier, D. Salinger, P. Vicini, 2014, Cancer Chemotherapy and Pharmacology.

Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005.

M. Mayes, B. Sandmaier, Roland Martin, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

E. Estey, J. Radich, B. Wood, 2013, Blood.

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

H. Deeg, J. Radich, S. Heimfeld, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.

H. Deeg, R. Storb, B. Sandmaier, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

H. Deeg, P. Hari, M. Sorror, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.

M. Maris, R. Storb, B. Sandmaier, 2002, Blood.

Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization.

I. Bernstein, J. Eary, B. Sandmaier, 1989, Experimental hematology.

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

R. Storb, B. Sandmaier, B. Storer, 2005, Bone Marrow Transplantation.

Nonmyeloablative allogeneic hematopoietic cell transplantation

R. Storb, B. Sandmaier, 2016, Haematologica.

Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013, Blood.

Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens

M. Sorror, R. Storb, B. Sandmaier, 2008, Bone Marrow Transplantation.

Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults.

Christopher G. Kanakry, B. Sandmaier, C. Hourigan, 2021, Transplantation and cellular therapy.

Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.

B. Sandmaier, J. Jacobberger, Y. Saunthararajah, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced Intensity Transplants for Lymphoma : Reduced Intensity versus Full Transplant 9

B. Sandmaier, J. Dipersio, C. Bollard, 2013 .

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

H. Deeg, B. Sandmaier, D. Maloney, 2011, Bone Marrow Transplantation.

Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, B. Storer, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

B. Sandmaier, F. Appelbaum, Stephanie J. Lee, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem Cell Transplantation in the Era of JAK Inhibition : Putting the Pieces Together 10

B. Sandmaier, J. Dipersio, P. Shaughnessy, 2013 .

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.

B. Wood, B. Sandmaier, T. Gooley, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2007, Blood.

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

F. Baron, B. Sandmaier, F. Appelbaum, 2019, Innovative Leukemia and Lymphoma Therapy.

malignancies nonmyeloablative conditioning for patients with hematologic HLA-matched unrelated donor hematopoietic cell transplantation after

S. Heimfeld, M. Maris, B. Sandmaier, 2013 .

Chapter 17 Nonmyeloablative Transplantation

F. Baron, B. Sandmaier, 2008 .

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.

M. Sorror, R. Storb, B. Sandmaier, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2003, Experimental hematology.

Non-myeloablative hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.

B. Sandmaier, D. Maloney, J. Pagel, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma

B. Sandmaier, J. Pagel, J. Rajendran, 2019, Clinical Cancer Research.

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients

B. Sandmaier, A. Karolak, D. Hockenbery, 2022, Clinical and translational science.

total body irradiation for relapsed and refractory mantle cell lymphoma Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy

R. Storb, B. Sandmaier, B. Storer, 2013 .

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

M. Maris, R. Storb, B. Sandmaier, 2011, Haematologica.

Differential L-Selectin Binding Activities of Human Hematopoietic Cell L-Selectin Ligands, HCELL and PSGL-1*

B. Sandmaier, R. Sackstein, Jack Y. Lee, 2001, The Journal of Biological Chemistry.

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.

H. Deeg, R. Storb, B. Sandmaier, 2019, Blood.

ADVANCES IN HEMATOPOIETIC CELL TRANSPLANTATION Conditioning regimens for hematopoietic cell transplantation: one size does not ﬁ t all

B. Sandmaier, B. Gyurkocza, 2014 .

Second allogeneic hematopoietic cell transplantation for relapse after first allografts

R. Storb, B. Sandmaier, D. Maloney, 2019, Leukemia & lymphoma.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

M. Sorror, B. Sandmaier, D. Maloney, 2019, Blood advances.

The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).

B. Sandmaier, T. Gooley, L. Holmberg, 2003, Clinical breast cancer.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

R. Storb, B. Sandmaier, D. Maloney, 2017, Blood advances.

peripheral-blood mononuclear cells in a canine transplantation model Durable engraftment of AMD3100-mobilized autologous and allogeneic

R. Storb, B. Sandmaier, G. Bridger, 2013 .

Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

R. Storb, B. Sandmaier, S. Fricker, 2005, Blood.

Confounding Factors Affecting the National Institutes of Health (NIH) Chronic Graft-Versus-Host Disease Organ-Specific Score and Global Severity

B. Sandmaier, B. Storer, Stephanie J. Lee, 2016, Bone Marrow Transplantation.

Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

R. Storb, B. Sandmaier, C. Anasetti, 1996, Stem cells.

Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".

R. Storb, B. Sandmaier, D. Hamlin, 2021, Transplantation and cellular therapy.

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies

R. Storb, B. Sandmaier, D. Hamlin, 2018, PloS one.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

B. Miller, B. Sandmaier, J. Pagel, 2015, Blood.

Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation

B. Sandmaier, D. Wilbur, W. Bethge, 2006, Leukemia & lymphoma.

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

M. Brechbiel, R. Storb, B. Sandmaier, 2003 .

Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

M. Brechbiel, R. Storb, B. Sandmaier, 2002, Blood.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

B. Sandmaier, J. Pagel, T. Gooley, 2016, Blood.

Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study

M. Brechbiel, R. Storb, B. Sandmaier, 2004, Transplantation.

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

H. Deeg, R. Storb, B. Sandmaier, 2022, Leukemia.

Vaccination with Theratope® (STn-KLH) as treatment for breast cancer

B. Sandmaier, L. Holmberg, 2004, Expert review of vaccines.

Characterization of Monoclonal Antibodies That Recognize Canine CD 34

R. Storb, B. Sandmaier, E. Wayner, 1998 .

Characterization of monoclonal antibodies that recognize canine CD34.

R. Storb, B. Sandmaier, E. Wayner, 1998, Blood.

M. Maris, R. Storb, F. Baron, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

M. Sorror, R. Storb, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An antibody that facilitates hematopoietic engraftment recognizes CD44.

R. Storb, B. Sandmaier, F. Appelbaum, 1990, Blood.

It takes a village ( of therapies ) to achieve optimal long-term outcomes for multiple myeloma

B. Sandmaier, J. Dipersio, C. Bollard, 2022 .

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

Brian R. Phillips, S. Heimfeld, B. Sandmaier, 2009, Cancer Chemotherapy and Pharmacology.

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

B. Sandmaier, J. Pagel, J. Rajendran, 2020, Bone Marrow Transplantation.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

P. Hari, R. Storb, B. Sandmaier, 2018, Haematologica.

Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells

B. Sandmaier, J. Hayflick, A. Stucki, 2000, British journal of haematology.

Reduced-intensity Allogeneic Transplantation Regimens

R. Storb, B. Sandmaier, 2016 .

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

B. Miller, R. Storb, B. Sandmaier, 2015, The Journal of Nuclear Medicine.

Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation

B. Sandmaier, B. Kornblit, Yun Chen, 2012, Chimerism.

Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

B. Sandmaier, D. Hamlin, D. Wilbur, 2012, Bioconjugate chemistry.

Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation

R. Storb, B. Sandmaier, D. Hamlin, 2010, Transplantation.

Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier.

R. Storb, B. Sandmaier, M. Thakar, 2010, Blood.

Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

B. Sandmaier, M. Thakar, J. Pagel, 2009, Bioconjugate chemistry.

Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

R. Storb, B. Sandmaier, M. Thakar, 2009, Cancer research.

The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation.

R. Storb, B. Sandmaier, P. Moore, 1999, Transplantation.

Biochemical characterization of a unique canine myeloid antigen.

I. Bernstein, B. Sandmaier, F. Appelbaum, 1991, Leukemia.

Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation.

B. Sandmaier, F. Appelbaum, R. Storb, 1989, Blood.

Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies

B. Sandmaier, J. Pagel, J. Rajendran, 2020, The Journal of Nuclear Medicine.

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.

B. Sandmaier, S. Mackinnon, R. Childs, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis – a single institution experience

R. Storb, B. Sandmaier, D. Maloney, 2017, Leukemia & lymphoma.

Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

H. Deeg, J. Radich, R. Storb, 2003, Blood.

Allogeneic hematopoietic cell transplantation after ﬂudarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

M. Maris, R. Storb, B. Sandmaier, 2004 .

Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center.

R. Storb, B. Sandmaier, A. Wald, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation

B. Sandmaier, B. Storer, M. Boeckh, 2015, Bone Marrow Transplantation.

Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model.

R. Storb, B. Sandmaier, F. Appelbaum, 1998, Blood.

Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release.

B. Sandmaier, P. Stayton, P. Tan, 1995, Immunological investigations.

J. Radich, M. Maris, R. Storb, 2005 .

Nonmyeloablative transplants: preclinical and clinical results.

R. Storb, B. Sandmaier, P. Mcsweeney, 2000, Seminars in oncology.

Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6.

B. Sandmaier, M. Boeckh, J. Hansen, 2017, Blood.

Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013, The oncologist.

Conditioning Regimens Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity

B. Sandmaier, B. Storer, N. Khera, 2014 .

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

R. Storb, B. Sandmaier, D. Maloney, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.

B. Sandmaier, M. Reddish, B. Longenecker, 1999, Journal of immunotherapy.

Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important?

B. Sandmaier, F. Appelbaum, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.

Brian R. Phillips, B. Sandmaier, B. Storer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2005, Blood.

Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts.

H. Deeg, R. Storb, B. Sandmaier, 1998, Blood.

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms

R. Storb, F. Baron, B. Sandmaier, 2019, Haematologica.

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

M. Sorror, R. Storb, B. Sandmaier, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD 45 antibody for conditioning in allogeneic − astatine-211-emitter α Durable donor engraftment after radioimmunotherapy using

R. Storb, B. Sandmaier, B. Storer, 2012 .

Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation

R. Storb, F. Baron, B. Sandmaier, 2006, Transplantation.

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML

B. Wood, R. Storb, B. Sandmaier, 2020, Leukemia.

Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

B. Wood, B. Sandmaier, B. Storer, 2012, Cancer.

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.

E. Estey, B. Sandmaier, B. Storer, 2011, Blood.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

M. Maris, R. Storb, B. Sandmaier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models

E. Estey, M. Sorror, B. Sandmaier, 2016 .

Development Of [211At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies

B. Sandmaier, R. Walter, D. Hamlin, 2022, Leukemia.

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

H. Deeg, K. Loeb, M. Sorror, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis

B. Sandmaier, M. Aljurf, M. Tallman, 2017, Cancer.

Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia

E. Estey, B. Sandmaier, F. Appelbaum, 2015, Haematologica.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2004, Blood.

Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013, Blood.

TRANSPLANTATION Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013 .

Multiple Myeloma Treatments for the Transplant-eligible and Non – Transplant-eligible Patient

B. Sandmaier, J. Dipersio, P. Shaughnessy, 2013 .

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

M. Maris, R. Storb, B. Sandmaier, 2007 .

Reduced intensity conditioned allograft yields favorable survival for older adults with B‐cell acute lymphoblastic leukemia

B. Sandmaier, H. Khoury, O. Ringdén, 2017, American journal of hematology.

It Is Easix to Predict Non-Relapse Mortality (NRM) of Allogeneic Stem Cell Transplantation (alloSCT)

R. Storb, B. Sandmaier, T. Luft, 2016 .

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recommendations for reporting post-transplant relapse in AML

B. Sandmaier, M. Linden, S. Devine, 2018, Bone Marrow Transplantation.

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for AML in First Morphological Remission

H. Deeg, M. Sorror, R. Storb, 2015 .

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

M. Maris, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Tallman, B. Sandmaier, M. Tallman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.

M. Bar, B. Sandmaier, R. Champlin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

OUTCOMES OF UCB TRANSPLANTATION ARE COMPARABLE IN FLT3+ AML: RESULTS OF CIBMTR, EUROCORD AND EBMT COLLABORATIVE ANALYSIS

F. Baron, B. Sandmaier, M. Labopin, 2016, Leukemia.

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

P. Hari, M. Sorror, M. Maris, 2019, Bone Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes

B. Sandmaier, A. Rezvani, Andrew R. Rezvani, 2013, Current opinion in hematology.

Reduced-Intensity Conditioning in Allogeneic StemCell Transplantation for Hematological Malignancies:A Historical Perspective

B. Sandmaier, M. Hallek, U. Holtick, 2011, Oncology Research and Treatment.

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia

B. Wood, B. Sandmaier, F. Appelbaum, 2022, Haematologica.

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

E. Estey, B. Sandmaier, M. Krem, 2021, Bone Marrow Transplantation.

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.

S. Heimfeld, R. Storb, B. Sandmaier, 2009, Blood.

Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody.

H. Deeg, R. Storb, B. Sandmaier, 1991, Blood.

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

M. Sorror, R. Storb, B. Sandmaier, 2020, Annals of Internal Medicine.

Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.

G. Colditz, B. Sandmaier, J. Dipersio, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-Intensity and Non-Myeloablative Conditioning Followed by Hematopoietic Cell Transplantation

B. Sandmaier, A. Ramakrishnan, 2012 .

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

M. Maris, R. Storb, B. Sandmaier, 2016 .

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors.

M. Maris, R. Storb, B. Sandmaier, 2020, Blood.

Effectiveness of addition of sirolimus to cyclosporine and mycophenolate mofetil-based graft-versus-host disease prophylaxis after unrelated nonmyeloablative hematopoietic cell transplantation: A multicentre phase III randomized trial

B. Sandmaier, B. Kornblit, 2019 .

Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect

R. Storb, B. Sandmaier, D. Maloney, 2018, Haematologica.

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

M. Bar, R. Storb, B. Sandmaier, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

B. Sandmaier, D. Maloney, T. Gooley, 2021, Blood advances.

Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2014, Blood.

Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.

M. Bar, M. Sorror, B. Sandmaier, 2019, Blood advances.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2018, Haematologica.

Current and Future Preparative Regimens for Bone Marrow Transplantation in Thalassemia a

H. Deeg, J Wagner, K. Sullivan, 1998, Annals of the New York Academy of Sciences.

Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model.

R. Storb, B. Sandmaier, T. Gooley, 2003, Experimental hematology.

Vaccination as a treatment for breast or ovarian cancer

B. Sandmaier, L. Holmberg, 2004, Expert review of vaccines.

Theratope® vaccine (STn-KLH)

B. Sandmaier, L. Holmberg, 2001, Expert opinion on biological therapy.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

E. Estey, M. Bar, B. Wood, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD

R. Storb, B. Sandmaier, T. Gooley, 2014, Bone Marrow Transplantation.

Extracorporeal Photopheresis in Addition to Pentostatin in Conditioning for Canine Hematopoietic Cell Transplantation: Role in Engraftment

R. Storb, B. Sandmaier, T. Gooley, 2010, Bone Marrow Transplantation.

Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation

R. Storb, B. Sandmaier, W. Leisenring, 2013, Chimerism.

Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation

J. Schiffer, R. Storb, B. Sandmaier, 2009, Haematologica.

Nonmyeloablative hematopoietic stem cell allografting

R. Storb, B. Sandmaier, A. Molina, 2000 .

This review focuses on recent developments in allogeneic hematopoietic stem cell transplantation in which improved understanding and control of immune modulation have led to nonmyeloablative conditioning regimens to establish allografts. By relying on a graft-versus-tumor effect for tumor eradicatio

R. Storb, B. Sandmaier, A. Molina, 2022 .

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.

M. Brechbiel, R. Storb, B. Sandmaier, 2003, Blood.

onmyeloablative Unrelated Donor Hematopoietic Cell ransplantation to Treat Patients with Poor-Risk , elapsed , or Refractory Multiple Myeloma

M. Sorror, M. Maris, R. Storb, 2007 .

Evaluation of Posttransplant Methotrexate to Facilitate Engraftment in the Canine Major Histocompatibility Complex-Haploidentical Nonmyeloablative Transplant Model

R. Storb, B. Sandmaier, M. Thakar, 2010, Transplantation.

Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.

H. Deeg, B. Sandmaier, F. Appelbaum, 1992, Blood.

Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model.

B. Sandmaier, M. Thakar, H. Kiem, 2009, Experimental hematology.

In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults".

P. Hari, B. Sandmaier, S. Davies, 2020, Blood advances.

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

R. Storb, B. Sandmaier, F. Appelbaum, 2022, Haematologica.

Relationship Between Pre-Transplant Nutritional Status and Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

B. Sandmaier, F. Appelbaum, M. Othus, 2022, Transplantation and cellular therapy.

Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)

E. Estey, B. Sandmaier, M. Othus, 2021, Leukemia & lymphoma.

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

H. Deeg, B. Wood, R. Storb, 2020, Cancers.

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission

B. Wood, R. Storb, B. Sandmaier, 2019, Bone Marrow Transplantation.

Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B‐Cell acute lymphoblastic leukemia

B. Sandmaier, H. Khoury, D. Weisdorf, 2017, Cancer.

Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients

S. Heimfeld, B. Sandmaier, B. Storer, 2015, Cancer Chemotherapy and Pharmacology.

Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Brian R. Phillips, B. Sandmaier, B. Storer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

B. Sandmaier, B. Storer, M. Boeckh, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

B. Sandmaier, W. Leisenring, A. Wald, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

M. Sorror, M. Maris, R. Storb, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis

H. Deeg, J. Radich, R. Storb, 2003 .

Engraftment of early erythroid progenitors is not delayed after non‐myeloablative major ABO‐incompatible haematopoietic stem cell transplantation

R. Storb, B. Sandmaier, D. Maloney, 2002, British journal of haematology.

Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging system

K. Vetter, B. Miller, Youngho Seo, 2022, Scientific Reports.

RECIPIENT PRETRANSPLANT INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY IN NONMYELOABLATIVE HCT

Brian R. Phillips, B. Sandmaier, B. Storer, 2014 .

Outcomes after hematopoietic cell transplantation among non-English- compared to English-speaking recipients

B. Sandmaier, Stephanie J. Lee, T. Gooley, 2022, Bone Marrow Transplantation.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

B. Sandmaier, M. Horowitz, R. Gale, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chronic Kidney Disease Following Non‐Myeloablative Hematopoietic Cell Transplantation

R. Storb, B. Sandmaier, B. Storer, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

allogeneic hematopoietic cell transplantation: a study of 193 patients Hepatic injury after nonmyeloablative conditioning followed by

M. Maris, R. Storb, B. Sandmaier, 2013 .

Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein.

R. Storb, B. Sandmaier, F. Appelbaum, 1996, Blood.

Nonmyeloablative Hematopoietic Cell Transplantation

C. Flowers, R. Storb, B. Sandmaier, 2001, Current opinion in oncology.

What radiation dose for DLA-identical canine marrow grafts?

B. Sandmaier, F. Appelbaum, R. Storb, 1988, Blood.

Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GVHD?

S. Heimfeld, P. Hari, R. Storb, 2016, Bone Marrow Transplantation.

M. Maris, R. Storb, B. Sandmaier, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors

H. Deeg, R. Storb, B. Sandmaier, 1996 .

Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation.

R. Storb, B. Sandmaier, B. Storer, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dog leukocyte antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by CD4 and CD8 T cells

J. Panse, R. Storb, B. Sandmaier, 2003, Transplantation.

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

R. Storb, B. Sandmaier, D. Maloney, 2012, Bone Marrow Transplantation.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

M. Sorror, M. Maris, R. Storb, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation for the Treatment of Patients with Poor-Risk, Relapsed or Refractory Multiple Myeloma

M. Sorror, M. Maris, R. Storb, 2007 .

Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.

M. Sorror, M. Maris, R. Storb, 2005 .

Urinary elafin and kidney injury in hematopoietic cell transplant recipients.

B. Sandmaier, G. Schoch, T. Gooley, 2015, Clinical journal of the American Society of Nephrology : CJASN.

DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment.

H. Deeg, B. Sandmaier, C. Yu, 1995, Blood.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for MDS and AML evolving from MDS

H. Deeg, B. Sandmaier, T. Gooley, 2016 .

131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

H. Deeg, M. Maris, R. Storb, 2005 .

Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age

R. Storb, F. Baron, B. Sandmaier, 2011, Haematologica.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

P. Hari, M. Maris, R. Storb, 2014, Haematologica.

HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Non-Malignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide.

T. Torgerson, R. Storb, B. Sandmaier, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation in the outpatient setting.

R. Storb, B. Sandmaier, B. Storer, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prevention of Graft‐versus‐Host Disease

H. Deeg, B. Sandmaier, R. Storb, 1995, Annals of the New York Academy of Sciences.

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

M. Sorror, R. Storb, B. Sandmaier, 2014 .

Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.

M. Bar, P. Hari, R. Storb, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

B. Sandmaier, W. Leisenring, S. Riddell, 2013, Blood.

An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation.

H. Deeg, B. Sandmaier, E. Bryant, 1996, Transplant Immunology.

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

B. Sandmaier, O. Frankfurt, B. Oran, 2014 .

Treatment of Fanconi anemia patients using fludarabine and low-dose total body irradiation followed by unrelated donor hematopoietic cell transplantation

R. Storb, B. Sandmaier, W. Leisenring, 2010, Bone Marrow Transplantation.

Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT

M. Sorror, M. Maris, R. Storb, 2006 .

T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma.

R. Storb, B. Sandmaier, J. Thompson, 2002, Cytotherapy.

Epitope Specificity of CD44 for Monoclonal Antibody–Dependent Facilitation of Marrow Engraftment in a Canine Model

R. Storb, B. Sandmaier, F. Appelbaum, 1998 .

Sensitivity of newly transplanted marrow to further irradiation.

B. Sandmaier, F. Appelbaum, R. Storb, 1988, Transplantation.

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

H. Deeg, M. Sorror, R. Storb, 2006, Leukemia.

Defining the intensity of conditioning regimens: working definitions.

B. Sandmaier, D. Blaise, M. Pasquini, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

B. Sandmaier, M. Pasquini, M. Horowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission

B. Sandmaier, M. Horowitz, H. Khoury, 2017, Cancer.

Reduced mortality after allogeneic hematopoietic-cell transplantation.

Michael Boeckh, Kieren A Marr, M. Sorror, 2010, The New England journal of medicine.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of Blood and Marrow Transplantation.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J. Radich, J Wagner, R. Storb, 2001, Blood.

New Strategies for Hematopoietic Stem Cell Transplantation

R. Storb, B. Sandmaier, R. Nash, 2000 .

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

B. Wood, M. Sorror, R. Storb, 2013, Leukemia.

Immunohistochemical characterization of canine acute graft-versus-host disease and erythema multiforme

B. Sandmaier, P. Moore, V. Affolter, 1998 .

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2003, Blood.

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

F. M. Stewart, B. Sandmaier, F. Appelbaum, 2020, Bone Marrow Transplantation.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Allen R. Chen, S. Piantadosi, C. Huff, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

J. Schiffer, M. Sorror, B. Sandmaier, 2017, Blood.

Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin

R. Storb, B. Sandmaier, P. Mcsweeney, 2013, Bone Marrow Transplantation.

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2003, Blood.

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.

H. Deeg, M. Maris, R. Storb, 2003, Blood.

Analysis) Transplants for Severe Aplastic Anemia (A 26-Year Retrospective Decreased Rejection and Improved Survival of First and Second Marrow

R. Storb, B. Sandmaier, W. Leisenring, 2013 .

Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis).

R. Storb, B. Sandmaier, W. Leisenring, 1998, Blood.

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

P. Hari, M. Sorror, M. Maris, 2020, Haematologica.

CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy

M. Sorror, B. Sandmaier, W. Leisenring, 2016, The Lancet. Haematology.

CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy

M. Sorror, B. Sandmaier, W. Leisenring, 2016, The Lancet. Haematology.

Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs

R. Storb, B. Sandmaier, D. Maloney, 2011, Haematologica.

Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

M. Maris, R. Storb, B. Sandmaier, 2009 .

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

J. Radich, M. Sorror, M. Maris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

E. Estey, M. Sorror, M. Maris, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas

M. Sorror, R. Storb, B. Sandmaier, 2010, British journal of haematology.

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2004, Blood.

'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex.

B. Sandmaier, M. Pettinger, T. Loughran, 1994, Experimental hematology.

Enhancement of natural killer activity by an antibody to CD44.

B. Sandmaier, H. Rossbach, E. Santos, 1993, Journal of immunology.

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.

M. Sorror, R. Storb, B. Sandmaier, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation

B. Sandmaier, B. Scott, 2016 .

Who is fit for allogeneic transplantation?

H. Deeg, B. Sandmaier, 2010, Blood.

Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2008, Cancer.

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

H. Deeg, M. Sorror, M. Maris, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes with myeloid malignancies.

B. Sandmaier, B. Scott, 2006, Hematology. American Society of Hematology. Education Program.

Reduced-Intensity Allogeneic Bone Marrow Transplantation

B. Sandmaier, F. Locatelli, C. Anasetti, 2006 .

Non-myeloablative transplantation.

B. Sandmaier, D. Maloney, S. Mackinnon, 2002, Hematology. American Society of Hematology. Education Program.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.

R. Storb, B. Sandmaier, D. Maloney, 2004, Blood.

Characterization of Malignant Lymphoma in Dogs and Use as a Model for the Development of Treatment Strategies

R. Storb, B. Sandmaier, F. Appelbaum, 1988 .

Conditioning regimens in bone marrow transplantation

I. Bernstein, R. Storb, B. Sandmaier, 1991 .

High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

S. Heimfeld, J. Panse, M. Sorror, 2005, Leukemia.

and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

S. Heimfeld, J. Panse, M. Sorror, 2005 .

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.

C. Flowers, M. Sorror, M. Maris, 2004, Blood.

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

C. Flowers, M. Sorror, M. Maris, 2004, Blood.

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

M. Maris, R. Storb, B. Sandmaier, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.

R. Storb, B. Sandmaier, D. Maloney, 2001, Blood.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

P. Hari, M. Sorror, R. Storb, 2009, Blood.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

R. Vij, B. Sandmaier, M. Aljurf, 2019, Haematologica.

Cytomegalovirus breakthrough and resistance during letermovir prophylaxis

B. Sandmaier, M. Boeckh, A. Greninger, 2023, Bone Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.

R. Storb, B. Sandmaier, A. Geddis, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Conditioning Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Kinetics of Engraftment in Patients with Hematological Malignancies Given

J. Radich, S. Heimfeld, R. Storb, 2009 .

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

J. Radich, S. Heimfeld, M. Maris, 2004, Blood.

Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes.

J. Thompson, R. Storb, B. Sandmaier, 2001, Blood.

Mesenchymal Stem Cells as Vehicles for Gene Delivery

S. Forestell, B. Sandmaier, J. Hendricks, 2000, Clinical orthopaedics and related research.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

S. Heimfeld, M. Maris, R. Storb, 2003, Blood.

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients

M. Sorror, B. Sandmaier, A. Mrhar, 2013, International journal of clinical pharmacology and therapeutics.

Use of trimetrexate for the prevention of graft-versus-host disease.

H. Deeg, B. Sandmaier, F. Appelbaum, 1989, Bone marrow transplantation.

Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century.

M. Maris, R. Storb, B. Sandmaier, 2001, Frontiers in bioscience : a journal and virtual library.

What is the role for donor natural killer cells after nonmyeloablative conditioning?

R. Storb, F. Baron, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age

R. Storb, B. Sandmaier, H. Heslop, 2011, British journal of haematology.

Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms

B. Sandmaier, A. Ramakrishnan, 2010, Expert review of hematology.

L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells. Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment.

B. Sandmaier, F. Appelbaum, G. Sale, 1988, Transplantation.

The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model.

B. Miller, B. Sandmaier, T. Gooley, 2019, Blood.

Cord-Blood Transplantation in Patients with Minimal Residual Disease.

B. Wood, M. Sorror, B. Sandmaier, 2016, The New England journal of medicine.

EASIX and mortality after allogeneic stem cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2019, Bone Marrow Transplantation.

Type of post‐grafting immunosuppression after non‐myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor abo incompatibility

R. Storb, B. Sandmaier, D. Maloney, 2002, British journal of haematology.

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2010, British journal of haematology.

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

B. Sandmaier, B. Gyurkocza, 2014, Blood.

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide

B. Sandmaier, D. Hockenbery, T. Randolph, 2022, Clinical and translational science.

Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.

R. Storb, B. Sandmaier, W. Leisenring, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after

B. Sandmaier, E. Warren, John A Thompson, 2011, Expert opinion on biological therapy.

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

M. Maris, R. Storb, B. Sandmaier, 2006 .

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2005 .

IMPDH pharmacogenetics in hematopoietic cell transplantation patients

B. Sandmaier, B. Storer, J. McCune, 2019 .

Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

B. Sandmaier, B. Storer, J. McCune, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.

R. Storb, B. Sandmaier, T. Luft, 2017, The Lancet. Haematology.

Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

J. Panse, M. Maris, R. Storb, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

H. Deeg, M. Sorror, M. Maris, 2014, Blood.

Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation

M. Maris, R. Storb, B. Sandmaier, 2005, British journal of haematology.

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.

M. Maris, R. Storb, B. Sandmaier, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mixed hematopoietic chimerism after hematopoietic stem cell allografts.

R. Storb, B. Sandmaier, P. Mcsweeney, 1999, Transplantation proceedings.

Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma

P. Hari, M. Sorror, R. Storb, 2008 .

Phase I/II multisite trial of optimally dosed clofarabine and low‐dose TBI for hematopoietic cell transplantation in acute myeloid leukemia

E. Estey, J. Radich, R. Storb, 2019, American journal of hematology.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

P. Hari, M. Sorror, M. Maris, 2011, JAMA.

Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.

R. Storb, B. Sandmaier, F. Appelbaum, 1995, Blood.

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

M. Sorror, R. Storb, B. Sandmaier, 2007, Blood.

The Impact Of Donor Type And ABO Incompatibility On Transfusion Requirements After Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2010 .

Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

M. Maris, R. Storb, B. Sandmaier, 2003, British journal of haematology.

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

C. Flowers, J. Radich, R. Storb, 2001, Annals of the New York Academy of Sciences.

Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, B. Storer, 2012, Blood.

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

R. Storb, B. Sandmaier, F. Appelbaum, 2009, Blood.

Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

R. Storb, B. Sandmaier, F. Appelbaum, 2009 .

Reduced Toxicity and Prompt Engraftment After Minimal Conditioning of a Patient With Fanconi Anemia Undergoing Hematopoietic Stem Cell Transplantation From an HLA-Matched Unrelated Donor

B. Sandmaier, H. Kiem, M. Pulsipher, 2003, Journal of pediatric hematology/oncology.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

F. M. Stewart, M. Sorror, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dog Leukocyte Antigen-Haploidentical Stem Cell Allografts After Anti-CD44 Therapy and Nonmyeloablative Conditioning in a Preclinical Canine Model

R. Storb, B. Sandmaier, T. Gooley, 2006, Transplantation.

A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients

B. Sandmaier, D. Salinger, P. Vicini, 2009, Clinical Cancer Research.

Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.

E. Estey, M. Sorror, B. Sandmaier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Costs of Second Allogeneic Hematopoietic Cell Transplantation

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013, Transplantation.

Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives

R. Storb, B. Sandmaier, D. Maloney, 2002, Journal of Clinical Immunology.

J. Radich, R. Storb, B. Sandmaier, 2002, International journal of hematology.

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning

M. Leppert, R. Storb, B. Sandmaier, 2004, Clinical Cancer Research.

Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome.

M. Maris, R. Storb, B. Sandmaier, 2003, Experimental hematology.

Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunosuppression after transplantation.

J. Panse, R. Storb, B. Sandmaier, 2005, Transplantation.

Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

M. Sorror, M. Maris, R. Storb, 2015, British journal of haematology.

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

J. Radich, M. Sorror, R. Storb, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

B. Sandmaier, O. Frankfurt, B. Oran, 2017, American journal of hematology.

(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

B. Sandmaier, H. Kiem, D. Hamlin, 2015, Human gene therapy.

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2010 .

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

M. Sorror, M. Maris, R. Storb, 2004 .

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

M. Maris, R. Storb, B. Sandmaier, 2019, The Lancet. Haematology.

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

M. Sorror, R. Storb, B. Sandmaier, 2008, British journal of haematology.

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.

M. Sorror, M. Maris, R. Storb, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Acute renal failure after nonmyeloablative hematopoietic cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004, Journal of the American Society of Nephrology : JASN.

Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century.

R. Storb, B. Sandmaier, D. Maloney, 2000, Transplantation proceedings.

Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease

B. Wood, B. Sandmaier, F. Appelbaum, 2019, Leukemia.

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning

F. Baron, B. Sandmaier, 2005, Current opinion in hematology.

C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients

Jeffrey K. Mito, P. Cresswell, B. Sandmaier, 2008, Clinical Cancer Research.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

C. Bloomfield, R. Larson, K. Mrózek, 2019, Leukemia.

A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, F. Appelbaum, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.

R. Storb, B. Sandmaier, D. Maloney, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

AJH_24959 222..231

B. Sandmaier, O. Frankfurt, B. Oran, 2019 .

C19orf48 Encodes a RCC-Associated Minor H Antigen 1 C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8 Cytotoxic T Cells from Renal Cell Carcinoma Patients Running Title: C19orf48 Encodes a RCC-Associated Minor H Antigen Authors:

Jeffrey K. Mito, P. Cresswell, B. Sandmaier, 2008 .

C 19 orf 48 Encodes aMinor HistocompatibilityAntigen Recognized by CD 8 + CytotoxicTCells from Renal Cell Carcinoma Patients

Jeffrey K. Mito, B. Sandmaier, E. Warren, 2008 .

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

B. Sandmaier, K. Wittrup, J. Pagel, 2020, Molecular Cancer Therapeutics.

Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies

B. Sandmaier, W. Bethge, 2005, Technology in cancer research & treatment.

Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies.

B. Sandmaier, W. Bethge, 2004, Seminars in oncology.

Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency.

B. Sandmaier, P. Stayton, P S Stayton, 1998, Biophysical journal.

Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

P. Hari, M. Sorror, M. Maris, 2015, Cancer.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004 .

transduced cytotoxic T lymphocytes Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally

R. Storb, B. Sandmaier, J. Zaucha, 2013 .

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Brian W. Miller, John M. Pagel, Brenda M. Sandmaier, 2015, Medical physics.

M. Maris, R. Storb, B. Sandmaier, 2003, British journal of haematology.

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.

M. Sorror, R. Storb, B. Sandmaier, 2008, Blood.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.

J. Radich, M. Maris, R. Storb, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age.

R. Storb, F. Baron, B. Sandmaier, 2009 .

What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624]

R. Storb, B. Sandmaier, F. Appelbaum, 1988 .

disease following prior therapy or antecedent hematologic disorders syndrome: similar outcomes in patients with de novo disease and syndrome or acute myeloid leukemia arising from myelodysplastic Hematopoietic cell transplantation in patients with myelodysplastic

B. Clurman, B. Sandmaier, B. Storer, 2013 .

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

B. Clurman, H. Deeg, R. Storb, 2007, Blood.

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

H. Deeg, B. Sandmaier, F. Appelbaum, 2023, Cancers.

Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission

R. Storb, B. Sandmaier, M. Othus, 2022, Bone Marrow Transplantation.

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

R. Storb, B. Sandmaier, F. Appelbaum, 2019, Haematologica.

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia

R. Storb, B. Sandmaier, M. Thakar, 2016, Bone Marrow Transplantation.

Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation

S. Heimfeld, R. Storb, F. Baron, 2010 .

Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

R. Storb, B. Sandmaier, D. Maloney, 2007 .

Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation.

M. Sorror, R. Storb, F. Baron, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

M. Sorror, R. Storb, B. Sandmaier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies

R. Storb, B. Sandmaier, 2009 .

Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation.

R. Storb, B. Sandmaier, B. Storer, 2011, Cytotherapy.

Immunomodulatory effects induced by CTLA4-Ig with donor PBMC infusion in canine MHC-haploidentical nonmyeloablative hematopoietic cell transplantation

R. Storb, B. Sandmaier, B. Storer, 2011 .

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

M. Norkin, B. Sandmaier, B. George, 2019, Blood advances.

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML

J. Radich, R. Storb, B. Sandmaier, 2005, Leukemia.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.

M. Maris, R. Storb, B. Sandmaier, 2006 .

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

M. Sorror, M. Maris, R. Storb, 2004 .

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Treatment of patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD)

M. Sorror, M. Maris, R. Storb, 2004 .

An antibody to CD44 enhances hematopoiesis in long-term marrow cultures.

B. Sandmaier, T. Gooley, H. Rossbach, 1996, Experimental hematology.

Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha.

B. Sandmaier, Y. Liu, E. Santos, 1995, Cellular immunology.

Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.

R. Storb, B. Sandmaier, D. Maloney, 2021, Transplantation and cellular therapy.

Durable engraftment of AMD3100-mobilized hematopoietic stem cells in a canine autologous and allogeneic model

R. Storb, B. Sandmaier, S. Fricker, 2005 .

The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells.

B. Sandmaier, P. Moore, L. Križanac-Bengez, 2008, Tissue antigens.

Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation

R. Storb, B. Sandmaier, D. Maloney, 2000 .

Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen

M. Maris, R. Storb, B. Sandmaier, 2003 .

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD

B. Wood, B. Sandmaier, P. Becker, 2018, American journal of hematology.

Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia

M. Bar, B. Wood, M. Sorror, 2016, Leukemia & lymphoma.

Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML.

H. Deeg, R. Storb, B. Sandmaier, 2022, Blood.

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

H. Deeg, J. Radich, M. Sorror, 2012, Blood.

Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.

S. Heimfeld, R. Storb, F. Baron, 2007 .

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.

H. Deeg, Emily A. Stevens, M. Sorror, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.

R. Storb, F. Baron, B. Sandmaier, 2005 .

Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning

S. Heimfeld, M. Maris, R. Storb, 2005 .

What is the role for donor NK cells after nonmyeloablative conditioning

R. Storb, F. Baron, B. Sandmaier, 2007 .

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

B. Sandmaier, R. Gale, H. Khoury, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Intracellular disposition of fludarabine triphosphate in human natural killer cells

S. Heimfeld, B. Sandmaier, Joanne Wang, 2009, Cancer Chemotherapy and Pharmacology.

Allogeneic transplant of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors.

H. Deeg, R. Storb, B. Sandmaier, 1996, Blood.

The influence of transfusions from unrelated DLA-matched or mismatched donors upon marrow grafts between DLA-identical canine littermates.

B. Sandmaier, F. Appelbaum, R. Storb, 1988, Transplantation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

M. Bar, P. Hari, R. Storb, 2012 .

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A M

M. Maris, R. Storb, B. Sandmaier, 2009 .

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.

M. Sorror, R. Storb, B. Sandmaier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs.

H. Deeg, B. Sandmaier, C. Yu, 1995, Blood.

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Effects of propylthiouracil on the biodistribution of an iodine-131-labeled anti-myeloid antibody in normal dogs: dosimetry and clinical implications.

I. Bernstein, J. Eary, B. Sandmaier, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

Urinary Elaﬁn and Kidney Injury in Hematopoietic Cell Transplant Recipients

B. Sandmaier, G. Schoch, T. Gooley, 2014 .

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.

B. Sandmaier, T. Gooley, H. Deeg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

M. Sorror, M. Maris, R. Storb, 2008 .

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

E. Estey, R. Storb, B. Sandmaier, 2010 .

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

R. Storb, B. Sandmaier, Richard J. Jones, 2006 .

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

M. Sorror, R. Storb, F. Baron, 2004 .

Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).

M. Maris, R. Storb, B. Sandmaier, 2004 .

Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease

H. Deeg, B. Wood, B. Sandmaier, 2019, Blood.

Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.

B. Sandmaier, D. Porter, K. Ballen, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Nonmyeloablative hematopoietic cell transplantation (HCT) for treatment of patients (pts) with fludarabine-refractory chronic lymphocytic leukemia (CLL) results in prolonged median survival.

J. Radich, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2005 .

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

R. Storb, B. Sandmaier, D. Maloney, 2012 .

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

R. Storb, B. Sandmaier, B. Storer, 2005, Bone Marrow Transplantation.

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

J. Radich, R. Storb, B. Sandmaier, 2004 .

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

S. Heimfeld, J. Panse, M. Sorror, 2004 .

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All Across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem.

B. Sandmaier, E. Nemecek, N. Majhail, 2022, Transplantation and cellular therapy.

FAILURE OF ANTITHYMOCYTE SERUM POSTGRAFTING TO OVERCOME “RESISTANCE” TO DLANONIDENTICAL CANINE MARROW GRAFTS1

H. Deeg, B. Sandmaier, F. Appelbaum, 1988, Transplantation.

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR

R. Larson, B. Sandmaier, F. Appelbaum, 2021, Leukemia.

Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative hlaidentical sibling ALLOGRAFTS

R. Storb, B. Sandmaier, D. Maloney, 2000 .

Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates.

H. Deeg, B. Sandmaier, F. Appelbaum, 1988, Transplantation.

Nonmyeloablative hematopoietic stem cell transplantation

M. Maris, R. Storb, B. Sandmaier, 2001 .

Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil

B. Sandmaier, D. Maloney, D. Mager, 2013, Journal of clinical pharmacology.

A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration‐Time Curve in Hematopoietic Cell Transplantation Recipients

B. Sandmaier, D. Salinger, P. Vicini, 2012, Journal of clinical pharmacology.

Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.

M. Sorror, R. Storb, B. Sandmaier, 2006 .

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation

B. Sandmaier, T. Gooley, M. Flowers, 2023, Blood advances.

Acute graft-versus-host disease

B. Sandmaier, M. Mohty, E. Holler, 2023, Nature Reviews Disease Primers.

Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting

R. Storb, B. Sandmaier, P. Mcsweeney, 1999, Annals of the New York Academy of Sciences.

Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning

S. Heimfeld, M. Maris, R. Storb, 2005, British journal of haematology.

Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

R. Storb, B. Sandmaier, D. Maloney, 2013 .

Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2011 .

Pre‐transplant comorbidity burden and post‐transplant chronic graft‐versus‐host disease

M. Sorror, R. Storb, B. Sandmaier, 2015, British journal of haematology.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2008 .

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

S. Heimfeld, P. Hari, R. Storb, 2016 .

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

H. Deeg, B. Sandmaier, F. Appelbaum, 2010 .

Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor.

R. Storb, B. Sandmaier, F. Appelbaum, 1989, Experimental hematology.

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

D. Neuberg, S. Sallan, B. Sandmaier, 2014 .

Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes

M. Sorror, R. Storb, B. Sandmaier, 2011 .

Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).

M. Sorror, R. Storb, B. Sandmaier, 2009 .

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

B. Sandmaier, D. Fredricks, S. Pergam, 2023, JAMA network open.

Apoptose induite par un anticorps anti-icam-r

B. Sandmaier, A. Stucki, 1999 .

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.

E. Estey, M. Sorror, B. Sandmaier, 2022, Blood.

A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).

R. Storb, B. Sandmaier, D. Maloney, 2006 .

Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older

B. Sandmaier, H. Heslop, J. Prchal, 2008 .

High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.

H. Deeg, B. Sandmaier, F. Appelbaum, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Maris, B. Sandmaier, D. Maloney, 2004 .

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2007 .

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

M. Sorror, R. Storb, F. Baron, 2005 .

Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation - A Single Center Experience.

B. Sandmaier, E. Petersdorf, L. Connelly-Smith, 2023, Transplantation and cellular therapy.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

M. Maris, R. Storb, B. Sandmaier, 2008 .

Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders

R. Storb, B. Sandmaier, 2007 .

Characterization of monoclonal antibodies that recognize canine CD34.

R. Storb, B. Sandmaier, E. Wayner, 1998, Blood.

Nonmyeloablative allogeneic hematopoietic cell transplantation

R. Storb, B. Sandmaier, 2016, Haematologica.

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

B. Miller, R. Storb, B. Sandmaier, 2015, Journal of Nuclear Medicine.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J Wagner, R. Storb, B. Sandmaier, 2001, Blood.

Antibody in Normal Dogs : Dosimetry and Clinical Implications Effects of Propylthiouracil on the Biodistribution of an Iodine-131-Labeled Anti-Myeloid

Darrell, I. Bernstein, J. Eary, 2006 .

Effects of Propyithiouracil on the Biodistribution of an Iodine-13 1-Labeled Anti-Myeloid Antibody in Normal Dogs : Dosimetry and Clinical Implications

I. Bernstein, J. Eary, B. Sandmaier, 2006 .

Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

B. Sandmaier, B. Storer, Stephanie J. Lee, 2013, Blood.

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.

R. Storb, B. Sandmaier, T. Luft, 2017, The Lancet. Haematology.

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation

H. Deeg, B. Sandmaier, E. Warren, 2007, Bone Marrow Transplantation.

Prevalence of Chromosomally Integr 6 in Patients with Human Herpesvir ated Human Herpesvirus us 6 e Central Nervous System Dysfunction

M. Sorror, R. Storb, B. Sandmaier, 2015 .

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

J. Schiffer, M. Sorror, B. Sandmaier, 2017, Blood.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

M. Norkin, B. Sandmaier, B. George, 2019, Blood advances.

B. Sandmaier, M. Aljurf, M. Grunwald, 2019, Haematologica.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

M. Norkin, R. Vij, W. Wood, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

E. Estey, M. Sorror, B. Sandmaier, 2018, Blood.

EASIX-1year and late mortality after allogeneic stem cell transplantation

M. Sorror, B. Sandmaier, T. Luft, 2023, Blood advances.

Donor Natural Killer (NK) Cell Immunotherapy Following Non-Myeloablative HLA-Haploidentical Hematopoietic Cell Transplantation (HCT) Improves Relapse and Progression Free Survival (PFS) in Patients with Hematologic Malignancies

S. Heimfeld, P. Hari, B. Sandmaier, 2016 .

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

J. Panse, M. Maris, R. Storb, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.

B. Sandmaier, D. Hamlin, D. Wilbur, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation.

R. Storb, B. Sandmaier, B. Storer, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

B. Sandmaier, R. Walter, D. Hamlin, 2023, Leukemia & lymphoma.